Sienna Raises $950K In New Capital

13-Apr-2016 Sienna Cancer Diagnostics Limited is pleased to announce that it recently raised approximately $950,000 in new capital. The funds were raised through the exercise of shareholder options and placements with new investors and long term shareholders. 

The funds, together with the receipt of approximately $680,000 from the R&D Tax Incentive and the continued product revenue stream, will be used to further the development of Sienna’s In-Vitro Diagnostic (IVD) product. The IVD is due for market launch in the United States and Europe towards the end of the 2016 calendar year.  The next major milestone leading to the launch of the IVD product is ISO13485 quality management system certification which is anticipated by the third quarter of the 2016 calendar year. The Company envisages a further capital raise prior to the launch of the IVD product. 


No Very

Captcha Image

Sign up for updates